Kaleido Biosciences Is A Clinical Stage Biotechnology Company Based In Massachusettswith Locations In Bedford And Lexingtonfounded In 2015 By Geoffery Von Maltzahn And Noubar Afeyanthe Company Focuses On Developing Microbiome Metabolic Therapiesmmtto Address Various Diseasesincluding Autoimmune Diseasesmetabolic Syndromeand Diabetes The Company Utilizes A Proprietary Platform That Enables The Discovery And Development Of Novel Therapies Targeting The Human Microbiomethis Platform Features A Library Of Over 1 500 Synthetic Glycanswhich Are Orally Administered And Selectively Metabolized By Enzymes In The Microbiomekey Products In Development Include Kb195 For Urea Cycle Disorderskb174 For Hepatic Encephalopathykb295 For Inflammatory Bowel Diseaseand Kb109 Targeting Sars Cov 2 Infection Kaleido Biosciences Has Raised Significant Fundingtotaling $165 5 Million Prior To Its Initial Public Offeringipo And Is Listed On Nasdaq Under The Ticker Symbol Kldothe Company Employs Around 82 People And Is Recognized For Its Innovative Approach In The Microbiome Therapeutics Field
No conferences found for this company.
| Company Name | Kaleido Biosciences Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
